Clinical trials: Advanced Malignant Tumors
Solid Tumor (Phase I)
A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration
This is a first-in-human (FIH), multicenter, open-label, phase I study of ABSK211 in participants with advanced solid tumors to evaluate safety, tolerability, PK and optimize the dosage.
- Trial name
- NCT07718165
- Testing
- ABSK211
- Where
- China
- Volunteers
- 247 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Advanced Solid Tumor
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid…
- Trial name
- NCT07414836
- Testing
- BG-C0979, Tislelizumab
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 84 people
- Sponsor
- BeOne Medicines
Advanced Malignancies, Tumors
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.
- Trial name
- NCT00421044
- Testing
- Patupilone/EPO906
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Tumors
Study Evaluating SKI-606 in Subject With Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of oral SKI-606 (100, 200, 300 or 400 mg) administered on a daily schedule to subjects with advanced malignant solid tumors and to define a maximum tolerated…
- Trial name
- NCT01001936
- Testing
- SKI-606
- Volunteers
- 28 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Neoplasms
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
The purpose of this study is to determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.
- Trial name
- NCT00962611
- Testing
- Copanlisib (Aliqopa, BAY80-6946)
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Bayer
Neoplasms
A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin.
- Trial name
- NCT00421811
- Testing
- ADH-1, melphalan
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Adherex Technologies, Inc.
Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
This study is open to adults with specific types of advanced soft tissue sarcoma. People with undifferentiated pleomorphic sarcoma (UPS) or myxofibrosarcoma (MFS) can join the study if they have a normal version of the TP53 gene.
- Conditions
- Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Myxofibrosarcoma (MFS)
- Trial name
- NCT06370871
- Testing
- Brigimadlin, Ezabenlimab, Gemcitabine
- Sponsor
- Boehringer Ingelheim
Solid Tumors
Phase II Clinical Trial of Uncaria Tomentosa (Cat´s Claw) in Patients With Advanced Solid Tumors
Cat's claw (Uncaria tomentosa) is a native amazonic plant that exhibits anti-inflammatory and antitumor properties. Patients and methods: This prospective phase II study will assess the effects of a 100-mg dose of a dry extract…
- Trial name
- cat´sclaw (NCT02045719)
- Testing
- uncaria tomentosa (cat´s claw)
- Where
- Brazil
- Volunteers
- 51 people
- Sponsor
- Faculdade de Medicina do ABC
Soft Tissue Sarcoma
APX005M and Doxorubicin in Advanced Sarcoma
This phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma.
- Trial name
- NCT03719430
- Testing
- Doxorubicin, APX005M
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Alexander Z. Wei, MD
Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to…
- Conditions
- Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma
- Trial name
- NCT05836571
- Testing
- Biopsy Procedure, Biospecimen Collection, Cabozantinib
- Where
- 27 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute LAO
Tumor, Solid, Tumor
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
- Conditions
- Tumor, Solid, Tumor, Advanced Solid Tumor
- Trial name
- NCT05661461
- Testing
- nab-sirolimus
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Aadi Bioscience, Inc.
Advanced Solid Tumors
An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma
Use PT-112 alone for Phase I dose escalation stage: advanced solid tumors, Phase I dose confirmation stage: advanced solid tumors. Phase II hepatocellular carcinoma (HCC).
- Trial name
- NCT03439761
- Testing
- PT-112 Injection
- Where
- China
- Volunteers
- 125 people
- Sponsor
- SciClone Pharmaceuticals
Solid Tumor, Lymphoma
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）
This is a Phase I study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, LB1410, is safe, tolerable and efficacious in participants with advanced solid tumors or lymphoma.
- Trial name
- NCT05357651
- Testing
- LB1410
- Where
- China
- Volunteers
- 100 people
- Sponsor
- L & L Bio Co., Ltd., Ningbo, China
Advanced Solid Tumor
A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-positive advanced solid tumors.
- Trial name
- NCT04941339
- Testing
- MRG002
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Shanghai Miracogen Inc.
Solid Tumors, Adult
A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid Tumors
This is a study of the clinical efficacy and mechanism study of tumor treatment vaccine (TTV, also known as Neo-BCV) in patients with recurrent and refractory advanced solid tumors.
- Trial name
- NCT05747339
- Testing
- tumor treatment vaccine injection
- Volunteers
- 50 people
- Sponsor
- Wuxi People's Hospital
Colorectal Cancer, Cholangiocarcinoma
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
- Conditions
- Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT06399757
- Testing
- APL-5125
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Apollo Therapeutics Ltd
Locally Advanced or Metastatic Solid Tumors
A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors
This study is an open-label, multicenter, dose-escalation, and extended-enrollment nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M05D1 in…
- Trial name
- NCT06349811
- Testing
- BL-M05D1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Cancers, Solid Tumors
Erlotinib in Combination With Pralatrexate in Advanced Malignancies
The goal of this clinical research study is to find the highest tolerable dose of the combination of erlotinib and pralatrexate that can be given to patients with advanced cancer.
- Trial name
- NCT01532011
- Testing
- Erlotinib, Pralatrexate
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
A Phase II study of temsirolimus in combination with standard chemotherapy (irinotecan; cyclophosphamide, doxorubicin and etoposide (CAE); cisplatin and etoposide (HiPE) and topotecan (TPT) followed by and additional six courses…
- Trial name
- NCT00808899
- Testing
- Temsirolimus, Irinotecan, Surgical Resection of Primary Tumor
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- St. Jude Children's Research Hospital
Advanced Solid Tumor, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
- Conditions
- Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04242199
- Testing
- INCB099280
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 182 people
- Sponsor
- Incyte Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.